These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25311071)

  • 41. Retracted: Spontaneous rectus sheath haematoma associated with rivaroxaban treatment.
    Tas Tuna A; Palabiyik O; Beyaz SG
    J Clin Pharm Ther; 2015 Aug; 40(4):486-8. PubMed ID: 25381906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bleeding incidence and real-life prescribing practices with dabigatran use in an acute care setting.
    Tran TH; Nguyen C; Lam T; Campbell P
    Consult Pharm; 2014 Nov; 29(11):735-40. PubMed ID: 25369188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A systematic review and adjusted indirect comparison of oral anticoagulants.
    Cui J; Wu B; Liu C; Li Z
    Orthopedics; 2014 Nov; 37(11):763-71. PubMed ID: 25361361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.
    Burghaus R; Coboeken K; Gaub T; Niederalt C; Sensse A; Siegmund HU; Weiss W; Mueck W; Tanigawa T; Lippert J
    Front Physiol; 2014; 5():417. PubMed ID: 25426077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".
    Chin PK; Wright DF; Florkowski CM
    Circulation; 2014 Nov; 130(22):e194. PubMed ID: 25421050
    [No Abstract]   [Full Text] [Related]  

  • 46. Is Dabigatran As Effective As Warfarin on Cardiac Thrombus in a Patient With Atrial Fibrillation? A Challenging Question.
    Sunbul M; Cincin A; Mammadov C; Mutlu B
    Am J Ther; 2016; 23(3):e974-6. PubMed ID: 25415546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
    Mensch A; Stock S; Stollenwerk B; Müller D
    Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
    Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expanding use of new oral anticoagulants.
    Weitz JI
    F1000Prime Rep; 2014; 6():93. PubMed ID: 25374671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spontaneous choroidal hemorrhage in a patient on dabigatran etexilate (Pradaxa).
    Kang TS; Lord K; Kunjukunju N
    Retin Cases Brief Rep; 2014; 8(3):175-7. PubMed ID: 25372432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Balancing ischaemia and bleeding risks with novel oral anticoagulants.
    Baber U; Mastoris I; Mehran R
    Nat Rev Cardiol; 2014 Dec; 11(12):693-703. PubMed ID: 25367652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Carney EF
    Nat Rev Nephrol; 2015 Jan; 11(1):3. PubMed ID: 25421829
    [No Abstract]   [Full Text] [Related]  

  • 53. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Doerr B; Mueller-Cohrs J; Pragst I; Morishima Y; Dickneite G
    Anesthesiology; 2015 Feb; 122(2):387-98. PubMed ID: 25419685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aortic dissection during rivaroxaban therapy: a challenging care.
    Béné J; Auffray JL; Auffret M; Caron J; Gautier S
    Acta Anaesthesiol Scand; 2015 Feb; 59(2):268. PubMed ID: 25394590
    [No Abstract]   [Full Text] [Related]  

  • 55. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.
    Hanna MS; Mohan P; Knabb R; Gupta E; Frost C; Lawrence JH
    Ann N Y Acad Sci; 2014 Nov; 1329(1):93-106. PubMed ID: 25377080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute thrombocytopenia after initiating anticoagulation with rivaroxaban.
    Mima Y; Sangatsuda Y; Yasaka M; Wakugawa Y; Nagata S; Okada Y
    Intern Med; 2014; 53(21):2523-7. PubMed ID: 25366015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Normal prothrombin times in the presence of therapeutic levels of apixaban--in-vivo experience from King's College Hospital.
    Patel JP; Chitongo PB; Czuprynska J; Roberts LN; Patel RK; Arya R
    Br J Haematol; 2015 Apr; 169(1):152-3. PubMed ID: 25312941
    [No Abstract]   [Full Text] [Related]  

  • 58. Myocardial ischemic events in 'real world' patients treated with dabigatran.
    Shah R
    Am J Med; 2014 Oct; 127(10):e19. PubMed ID: 25311071
    [No Abstract]   [Full Text] [Related]  

  • 59. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Rosenzweig M; Lane DA; Lip GY
    Am J Med; 2014 Apr; 127(4):329-336.e4. PubMed ID: 24361757
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.